Marcelo Bigal, Ventus Therapeutics CEO

No­vo Nordisk joins No­var­tis, Roche in NL­RP3 are­na, bet­ting $70M cash on NASH, car­diometa­bol­ic us­es

As a drug tar­get, the NL­RP3 in­flam­ma­some has drawn se­ri­ous in­ter­est from Big Phar­ma, in­spir­ing a se­ries of M&A deals from No­var­tis and Roche on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.